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Accurate ascertainment of the number of children 
living with human immunodeficiency virus (HIV) is 
important to plan paediatric and adolescent health 
services. In Europe, the first generation of perinatally 
HIV-infected survivors are transferring to adult care 
and their health needs are unknown. We undertook 
an online survey of HIV cohort studies participating 
in the EuroCoord Network of Excellence to ascertain 
the number of perinatally HIV-infected (pHIV) patients 
included, to compare it with those published by the 
European Centre for Disease Prevention and Control 
(ECDC) and the World Health Organization (WHO) and 
to assess the ability of countries to follow up pHIV 
patients after transfer to adult care. At the end of 
2013, 16 countries in EuroCoord reported 8,229 pHIV 
patients in follow-up in cohorts, compared with 5,160 
cumulative diagnoses reported by the ECDC in the 
same area. Follow-up of pHIV patients after transfer to 
adult care varied. It is likely that the number of diag-
noses of perinatal HIV reported to ECDC is an underes-
timate, although this varies by country. Further work 
is needed to refine estimates and encourage follow-up 
in adult HIV cohorts to investigate long-term outcomes 
and improve the care of the next generation of chil-
dren with HIV.
Background
Since 2008, the European Centre for Disease Prevention 
and Control (ECDC) and the World Health Organization 
Regional Office for Europe (WHO/Europe) have jointly 
coordinated surveillance of human immunodeficiency 
virus (HIV) and acquired immunodeficiency syndrome 
(AIDS) in Europe, covering all 53 countries in the 
European region [1]. HIV is a major public health issue 
in Europe, with an estimated 136,000 new infections 
diagnosed in 2013, of which 29,000 were from the 
European Union and European Economic Area (EU/
EEA, comprising 30 countries) and 80,000 from the 
Russian Federation [1]. ECDC/WHO data suggest that 
the cumulative number of HIV diagnoses attributed to 
mother-to-child transmission (henceforth referred to as 
perinatally HIV-infected (pHIV) patients) in the EU/EEA 
region was 5,636 from when reporting began to the 
end of 2013 [1].
The estimated number of new infections in children 
globally has decreased from 450,000 in 2005 to 
240,000 in 2013, mainly due to scale-up of interven-
tions to prevent mother-to-child transmission (MTCT), 
while access to antiretroviral therapy (ART) for infected 
children has increased [1,2]. As a consequence, the face 
of the paediatric HIV epidemic is rapidly changing, par-
ticularly in Western Europe where, although few infants 
are born with HIV, there are still new paediatric diagno-
ses in migrant children who were born elsewhere, pre-
dominantly sub-Saharan Africa [3]. Furthermore, due to 
widespread use of ART, an increasing proportion of the 
pHIV population are surviving into adulthood and now 
transferring to adolescent and adult HIV care.
Although in most of Western Europe, pHIV young 
people form a relatively small group, they are likely 
to have different health needs compared with young 
adults with sexually acquired HIV [4,5]. Small studies 
have suggested that as pHIV patients enter adult life 
they are at high risk of mortality [6], co-morbidities [7], 
treatment failure [8] and disengagement from care [9]. 
They may have additional challenges which can affect 
health outcomes, including neurodevelopment and 
mental health issues [10-12], stigma and discrimination 
[13], HIV disclosure issues [14] and parental loss [15]. 
Critically, the adolescent period coincides with broader 
social transformations in young people’s lives which 
can substantially shape their transition experience as 
well as health outcomes [16,17].
A comprehensive understanding of the epidemiol-
ogy of HIV among children and young people at the 
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national and European level is important for efficient 
planning of health services. Cohort studies provide 
a unique opportunity to monitor the changing epide-
miology of HIV in this group longitudinally and to fol-
low pHIV young people during transition to adulthood 
and beyond. Therefore, we undertook a survey of HIV 
cohort studies participating in the EuroCoord Network 
of Excellence [18] to ascertain the number of pHIV 
patients included and their geographical distribution. 
We compared these estimates with those published by 
ECDC/WHO which are largely derived from surveillance 
of new HIV diagnoses reported by countries in Europe. 
In addition, we explored the extent to which European 
cohorts were able to continue follow-up of this group 
as they transition from paediatric to adult care.
Methods
The EuroCoord Network (www.eurocoord.net) con-
sists of four founding networks: Concerted Action 
on SeroConversion to AIDS and Death in Europe 
(CASCADE), a network of adult seroconverter cohorts, 
Collaboration of Observational HIV Epidemiological 
Research in Europe (COHERE), a collaboration of paedi-
atric and adult cohorts, EuroSIDA, a large cohort of adult 
European patients, and Paediatric European Network 
for the Treatment of AIDS - European Pregnancy and 
Paediatric HIV Cohort Collaboration (PENTA-EPPICC), 
Figure
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a multinational network of centres participating in 
clinical trials and observational studies of HIV-infected 
pregnant women and children.
Within EuroCoord, a cross-network working group 
(the ‘Kids to Adults Working Group’) was established 
to investigate the number of pHIV patients included 
in adult and paediatric cohorts in each Network, and 
the degree to which paediatric and adult cohorts 
were linked and able to follow up young people after 
transition to adult care. This Group collaborated with 
the EuroCoord Data Management and Harmonisation 
Group to obtain data from the 2013 EuroCoord Data 
Inventory survey (a sample questionnaire can be found 
here: https://chip-crf.info/wp4/survey.php) which col-
lects metadata from cohorts within EuroCoord on an 
annual basis, including the number of patients ever 
reported to each cohort who were perinatally infected. 
It was not possible to also request data on the num-
ber alive and/or in care as most cohorts did not have 
national coverage, and therefore would not be able to 
differentiate a patient moving to a different clinic from 
a patient emigrating or dying, and many cohorts were 
not able to follow patients after transition to adult care 
and therefore did not have data on patient outcomes in 
adult care. Data on age and age at transition were not 
collected. An additional questionnaire was sent to four 
cohorts which had recently joined the PENTA-EPPICC 
network but who were yet to complete the EuroCoord 
Data Inventory. Cohorts varied from single hospital 
sites to studies with regional or national coverage, and 
thus we reasoned that in most cases, they represented 
a subset of the true size of the pHIV population in each 
country. The survey and the additional questionnaires 
were completed by cohort principal investigators, data 
managers and/or statisticians.
Descriptive statistics were used, and analyses were 
restricted to cohorts in the EU/EEA area (i.e. exclud-
ing Russia, Switzerland and Ukraine) in order to pro-
vide comparability to published ECDC estimates of 
the cumulative number of HIV diagnoses in persons 
infected through mother-to-child transmission since 
the start of reporting (which varied by country) and to 
the end of 2013 [1]. All analyses were undertaken using 
STATA 13.
Results
At the time of the survey in 2013, EuroCoord included 
45 cohorts across 16 countries in the EU/EEA area in 
Europe; The Figure shows the 26 EU/EEA countries and 
the number of pHIV patients enrolled. Within the EU/
EEA area, 10 countries did not have any HIV cohorts in 
EuroCoord (Bulgaria, Croatia, Czech Republic, Estonia, 
Finland, Hungary, Latvia, Lithuania, Slovakia and 
Slovenia) and additionally, the Norwegian cohort in 
EuroCoord reported having no data on pHIV patients. 
The other 15 countries reported having pHIV patients 
represented in cohort studies (Figure).
Cohorts in France, Italy, Spain and the United Kingdom 
(UK) reported the largest number of pHIV patients ever 
in follow-up, with over 1,000 patients per country by the 
end of 2013. The German cohort reported between 500 
and 999 patients, and Belgium, Denmark, Ireland, the 
Netherlands, Poland and Portugal reported between 
100 and 499 patients. Austria, Greece, Romania 
and Sweden each reported fewer than 100 patients. 
Together, all 16 countries (including Norway) reported 
a total of 8,229 pHIV patients ever followed up in HIV 
cohorts in the EU/EEA area. Spain had three paediatric 
cohorts, and any double counting of patients had been 
removed before data submission to the EuroCoord Data 
Inventory. However, overlap between adult and paedi-
atric cohorts could have occurred in France, Germany, 
Italy, Spain and the UK, but not in Belgium. This effect 
was potentially largest in France, whose adult cohorts 
reported 1,608 pHIV patients, some of whom could 
have been included in more than one adult cohort or 
in the 698 patients reported by the paediatric cohort. 
When restricted to paediatric-only cohorts, a total of 
5,595 pHIV patients were reported.
The number of pHIV patients in each EU/EEA coun-
try included in EuroCoord is compared with the num-
ber reported to ECDC/WHO in the Table. There were 
16 EuroCoord countries with HIV cohorts reporting 
pHIV patients compared with 30 EU/EEA countries 
with ECDC estimates of perinatal HIV diagnoses. The 
8,229 patients with perinatal HIV infection in cohorts 
in EuroCoord in these 16 countries compare to 5,160 
cumulative diagnoses reported to ECDC in the same 
countries. Countries varied in the degree to which HIV 
cohort estimates were similar to ECDC estimates. For 
Austria, Denmark, the Netherlands and the UK, cohort 
estimates were within a +/− 25% window of ECDC 
estimates. For Germany, Greece, Norway, Portugal, 
Romania and Sweden, cohort numbers were less than 
half the ECDC estimates. However, in France, Italy and 
Spain (three of the four largest MTCT patient cohorts) 
the reverse was true, with cohort estimates being more 
than five times higher than ECDC estimates, assuming 
no double counting of patients in cohorts.
Within the EuroCoord cohorts, the extent to which pae-
diatric and adult cohorts were linked for follow-up of 
pHIV patients varied widely across the 15 countries 
with pHIV cohorts (i.e. excluding Norway). In Denmark, 
Greece, Netherlands and Romania, paediatric and 
adult data were already held in the same database; 
however these countries accounted for only 397 (5%) 
of the 8,229 patients. In the UK and Ireland, mecha-
nisms for linkage of paediatric and adult data were in 
progress, through a multifaceted approach including 
extension of the national paediatric cohort (‘CHIPS’) 
[3] to monitor patients in adult care (‘CHIPS+’) [19], 
enrolment of a subsample of the paediatric cohort into 
the Adolescents and Adults Living with Perinatal HIV 
(AALPHI) cohort, which also includes a group of HIV-
negative sibling controls [20], and linkage to national 
surveillance data and the UK Collaborative HIV Cohort 
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Table
Patients who acquired HIV through mother-to-child transmission included in EuroCoord cohorts (n = 5,595) and reported 
to ECDC surveillance to the end of 2013 (n = 5,636)
Data source EuroCoord cohorts ECDC
EU/EEA 
country
Number of 
adult cohorts 
reporting MTCT 
patientsa
Number of 
paediatric-
only 
cohorts
Coverage of 
paediatric 
cohort
Number 
of MTCT 
patients in 
adult cohorts
Number of 
MTCT patients 
in paediatric 
cohorts
Total number 
of MTCT 
patients
Number 
of MTCT 
patients
Proportion of 
patients in 
EuroCoord/ECDC
Austria 1 0 NA 53 0 53 54 98%
Belgium 1 1 Single hospital 65 163 228 428 53%
Bulgaria 0 0 NA 0 0 0 19 NA
Croatia 0 0 NA 0 0 0 13 NA
Cyprus 0 0 NA 0 0 0 3 NA
Czech 
Republic 0 0 NA 0 0 0 6 NA
Denmark 0 1 Single hospital 0 100 100 96 104%
Estonia 0 0 NA 0 0 0 46 NA
Finland 0 0 NA 0 0 0 24 NA
France 3 1 Multiregional 1,608 698 2,306 388 594%
Germany 2 1 Multiregional 21 4 25 326 8%
Greece 1 0 NA 0 9 9 64 14%
Hungary 0 0 NA 0 0 0 11 NA
Iceland 0 0 NA 0 0 0 1 NA
Ireland 0 1 National 0 95 95 75 127%
Italy 2 1 Multiregional 22 1,557 1,579 136 1,161%
Latvia 0 0 NA 0 0 0 59 NA
Lithuania 0 0 NA 0 0 0 3 NA
Luxembourg 0 0 NA 0 0 0 7 NA
Malta 0 0 NA 0 0 0 0 NA
The 
Netherlands 1 0 National 261 0 261 277 94%
Norway 0 0 NA 0 0 0 76 0%
Poland 0 1 Single hospital 0 111 111 193 58%
Portugal 0 1 Single hospital 0 40 40 393 10%
Romania 0 1 Single hospital 0 27 27 243 11%
Slovakia 0 0 NA 0 0 0 0 NA
Slovenia 0 0 NA 0 0 0 7 NA
Spain 2 3 National 278 1,184 1,462 86 1,700%
Sweden 1 Single hospital 0 75 75 203 37%
United 
Kingdom 1 1 National 131 1,727 1,858 2,399 77%
Total for 
countries 
with 
EuroCoord 
data 
available
14 14 NA 2,439 5,790 8,229 5,160 159%
Total all 
countries 14 14 NA 2,439 5,790 8,229 5,636 NA
ECDC: European Centre for Disease Prevention and Control; EU/EEA: European Union and European Economic Area; HIV: human 
immunodeficiency virus; NA: not applicable.
a Adult cohorts may include paediatric patients while paediatric cohorts include children up to age 16 or 18 years or remaining in paediatric 
care.
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Study (CHIC) adult HIV cohort to enable data sharing 
and tracking of patients lost to follow up [21]. Belgium, 
Poland, Portugal and Sweden reported that paediatric 
and adult data linkage was possible although not yet in 
place. Austria and Spain reported that datasets could 
not be linked. For France, Germany and Italy, the cohort 
respondent did not know if linkage was possible.
Discussion
Results from this survey of adult and paediatric HIV 
cohorts in Europe indicated that, across 16 countries in 
the EU/EEA area, the estimated number of pHIV patients 
in cohorts was at least 5,595, and potentially more than 
8,000. The largest numbers were in cohorts in France, 
Italy, Spain and the UK, which together accounted for 
ca 88% (7,205) of the 8,229 patients. These four coun-
tries all have dedicated multisite paediatric cohort 
studies, with good geographical coverage, with the 
proportion of perinatal HIV diagnoses included in the 
Spanish [22] and UK [3] national cohorts approaching 
100%. However, the comparability of these countries’ 
estimates to ECDC/WHO data varied considerably. 
EuroCoord cohort numbers for France, Italy and Spain 
were at least five times higher than ECDC/WHO new 
HIV diagnoses. For Italy, cohort data are not linked to 
the Centro Operativo AIDS national reporting system (L 
Galli, personal communication, December 2014), and it 
is likely that the French and Spanish cohorts similarly 
operate without always reporting to ECDC/WHO and 
warrant further investigation. Part of the reason for 
the discrepancy may be that in France, Italy and Spain, 
HIV surveillance and reporting to ECDC only started in 
2003 or later, and cases diagnosed before that time 
and included in these longstanding cohorts were there-
fore not reported. Furthermore, Italy and Spain only 
achieved national coverage in terms of reporting to 
ECDC/WHO in 2012 and 2013, respectively, and not all 
regions participated in earlier years of surveillance [1].
In contrast, in the UK, where data from the national 
paediatric cohort are sent to ECDC, there was more 
comparability, although the number reported by the 
EuroCoord cohorts was lower than that reported to 
ECDC. This is likely to be because the paediatric cohort 
estimates include all HIV diagnoses among children 
younger than 16 years while the national surveillance 
also includes new perinatal HIV diagnoses in adults 
(e.g. perinatally infected adults born and diagnosed 
abroad and entering an adult cohort without prior pae-
diatric care in the UK). As this latter group increases 
with improved paediatric access to ART in Africa, 
estimates will deviate further in the future. For other 
countries, perinatal HIV infections that were diagnosed 
abroad may not be reported in the European country of 
arrival as ‘new diagnoses’, but may be eligible to join 
a cohort, potentially contributing to higher numbers in 
cohorts compared with ECDC data. Conversely, children 
who die after being reported as new diagnoses may 
never be eligible to join a cohort and thus contribute to 
higher numbers for ECDC compared with cohort data.
Although Austria, Denmark and the Netherlands had 
few pHIV patients overall, the EuroCoord estimates 
were very similar to ECDC estimates; in particular for 
Austria and the Netherlands, cohort data are used 
for surveillance and reported to ECDC (R Zangerele, 
personal communication, December 2014; C Smit, 
personal communication, June 2015). The lack of HIV 
cohorts in EuroCoord from many of the Baltic and 
Balkan states highlights the importance of reliable 
reporting of new cases to ECDC/WHO in these regions, 
as many countries in these areas are experiencing large 
and rapidly growing HIV epidemics [19,23]. In Romania, 
only a single hospital cohort participates in EuroCoord, 
but ECDC/WHO data originate from nine regional HIV/
AIDS centres who all report to the centralised National 
Institute for Infectious Diseases (M Mardarescu, per-
sonal communication, June 2015).
Data on pHIV patients from six of the 14 countries with 
paediatric cohorts within EuroCoord were from single 
hospitals. Some of these countries were large, includ-
ing Poland, Portugal and Romania, and these single 
hospitals will underestimate numbers of pHIV patients 
in the country. Similarly, France, Germany and Italy 
reported the number of pHIV patients from multire-
gional centres, for which coverage of the entire country 
is not known, again suggesting that we are underesti-
mating the size of the pHIV population in these coun-
tries. Certainly countries with national cohorts as well 
as links to national surveillance should provide a more 
representative picture.
Cohorts from only four countries (Denmark, Greece, the 
Netherlands and Romania) with small numbers of pHIV 
patients reported that paediatric and adult data are 
held together, thus enabling continued uninterrupted 
data collection after transfer to adult care. Many chil-
dren in paediatric care in Europe today will soon trans-
fer to adult clinics which are already part of existing 
HIV cohort studies, so the lack of linkage constitutes a 
missed opportunity to monitor long-term outcomes in 
this group. Investment in linkages is crucial to inform 
future clinical care practice and policies for pHIV popu-
lations in high- and middle-income settings in Europe 
and elsewhere.
Globally more than 200,000 HIV-infected children are 
born each year despite success in scaling up initiatives 
for the prevention of MTCT, and more than 90% live in 
sub-Saharan Africa [2]. Improvements in early diagno-
sis, linkage to care and prompt initiation of ART mean 
that many will survive to adulthood. African children 
have had access to ART for a considerably shorter time 
than children from well-resourced settings, and out-
comes for young people with perinatal HIV in Europe 
will signal the direction of future care of HIV-infected 
African children, highlighting the importance of ensur-
ing long-term follow-up of European pHIV patients. 
Children and young people with perinatally acquired 
HIV are unique in terms of their disease and treatment 
history. Many have been and more will be treated from 
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infancy or in early life [24,25], with unknown outcomes 
in adulthood in terms of long-term treatment options, 
the effect of perinatal infection on accelerated ageing 
or life expectancy, and the impact of life-long HIV and 
ART exposure on future generations of pHIV patients. 
Therefore, it is critical that adult care providers are 
aware of the importance of identifying this group as 
perinatally HIV-infected, maximise their retention 
into adult care and monitor their health needs and 
outcomes.
Conclusion
In summary, it is likely that the overall number of diag-
noses of perinatal HIV reported to ECDC/WHO may 
underestimate the true number of pHIV cases under 
care in the EU/EEA. Countries varied in the degree to 
which their figures differed from those of ECDC/WHO, 
with few cohorts having national coverage and/or being 
integrated into national surveillance reporting systems. 
Possible reasons for higher cohort numbers in coun-
tries such as France, Italy and Spain include cohorts 
recruiting before the start of reporting to ECDC/WHO, 
poor coverage of reporting to ECDC/WHO historically 
and inclusion of cases previously diagnosed abroad. 
Potential reasons for higher numbers in ECDC/WHO 
data for countries such as Romania and the UK include 
better coverage of reporting new diagnoses and inclu-
sion of cases who died and therefore were not eligible 
to join some cohorts. Importantly, for many countries 
without HIV cohorts, ECDC/WHO data represent the 
best source of data on numbers of pHIV patients.
Further work is needed to link cohorts to national 
reporting systems country by country, to improve epi-
demiological estimates of the size of the pHIV popu-
lation in Europe. It is also critical to ensure that adult 
cohort studies are ready to identify and track young 
people with perinatal HIV in their care. It is important 
that linkage occurs between paediatric and adult data-
sets to ensure continuity of monitoring and the ability 
to investigate long-term outcomes, in order to improve 
the care of the next generation of children with HIV 
infection and HIV exposure.
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